Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Myriad Genetics (MYGN) PT Raised to $37 at Needham & Company
February 6, 2019 8:05 AM ESTNeedham & Company analyst Stephen Unger raised the price target on Myriad Genetics (NASDAQ: MYGN) to $37.00 (from $36.00) while maintaining a Strong Buy rating.
Unger commented, "We are updating our financial model for MYGN following last night's release of FY2Q19 results. Our... More
Myriad Genetics (MYGN) Misses Q2 EPS by 3c; Offers 3Q & FY19 EPS/Revenue Outlook
February 5, 2019 4:31 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.38, $0.03 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $216.8 million versus the consensus estimate of $216.73 million.
"This quarter we saw a return to revenue growth for our hereditary cancer business, an... More
